Dhampur Bio Organics Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Dhampur Bio Organics Ltd trades at ₹112, in a confirmed uptrend and 23 weeks into that stage. That is +9.8% against its own 200-day average. It sits at 76% of a 52-week range of ₹71 to ₹125. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is in a confirmed uptrend — week 23 of stage 2, confirmed. At ₹112 it trades +9.8% versus its 200-day average and sits at 76% of its 52-week range (₹71–₹125).

Against the market, two honest reads. Cumulative: over the last 3.9 years the stock moved −32% while the NIFTY 500 moved +49% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 52nd percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Dhampur Bio Organics Ltd trades at 26.5× P/E, mid-range by its own standards (52nd percentile). Its long-run median P/E is 26.3×, measured across 3.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 26.5× is mid-range by its own standards (52nd percentile), against a long-run median of 26.3× measured over 3.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +71.5% against a +8.0% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the −12.8%/yr price move, ~−38.7%/yr came from earnings growth and ~+25.9 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Dhampur Bio Organics Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

49.9/100 — rank 10 of 20 in Sugar · 72% evidence confidence

Dhampur Bio Organics Ltd scores 49.9 out of 100 against the 20 companies it is compared with in Sugar, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 21.4 + 6.1 + 9.5 + 12.9 = 49.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Dhampur Bio Organics Ltd reported ₹533 Cr of revenue in the Jun 26 quarter, +8.3% year on year. The last full year, FY26, came in at ₹2,109 Cr. The last four reported quarters add to ₹2,037 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

Dhampur Bio Organics Ltd reported ₹533 Cr of revenue in the Jun 26 quarter, +8.3% year on year. The last full year, FY26, came in at ₹2,109 Cr. The last four reported quarters add to ₹2,037 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

FY26 revenue came in at ₹2,109 Cr (+13.3% on the year). The latest quarter (Jun 26) printed ₹533 Cr, +8.3% year on year.

Acceleration check: trailing-twelve-month revenue grew +8.0% over the last 4 quarters against +8.0%/yr over the last 8 — stabilising.

→ Revenue grew — did margins hold as it scaled? Next: 2.0% this quarter (+0.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Dhampur Bio Organics Ltd's operating margin is 2.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.0% to 12.0%. The current quarter is running below every full year in that window.

Dhampur Bio Organics Ltd's operating margin is 2.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.0% to 12.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 2.0%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.0%–12.0%.

🚨 Why the margin moved: operating margin went −0.1 pp year on year while gross margin went +2.6 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins held — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Dhampur Bio Organics Ltd earned ₹37.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹25.0 Cr. That is 6.9% of the quarter's revenue. The same quarter a year earlier lost ₹22.0 Cr. 5 of the last 12 reported quarters were loss-making.

Dhampur Bio Organics Ltd earned ₹37.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹25.0 Cr. That is 6.9% of the quarter's revenue. The same quarter a year earlier lost ₹22.0 Cr. 5 of the last 12 reported quarters were loss-making.

Jun 26 profit was ₹37.0 Cr, null year on year. On the full year, FY26 printed ₹25.0 Cr (+66.7%).

→ Profit rose — but did the cash follow? Next: 290% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 290% of Dhampur Bio Organics Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹220 Cr of operating cash against ₹25.0 Cr of profit. After ₹36.0 Cr of capital spending, ₹184 Cr was left as free cash.

FY26: operating cash of ₹220 Cr against reported profit of ₹25.0 Cr, leaving free cash of ₹184 Cr after ₹36.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 290% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 290%: the cash cycle tightened 96 days between FY22 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 2.2× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹349 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Dhampur Bio Organics Ltd's cash conversion cycle runs 216 days in FY26, down from 312 days in FY22. Capital spending ran ₹349 Cr over the last 3 years. At FY26 sales of ₹2,109 Cr each day of that cycle holds about ₹5.8 Cr, so roughly ₹1,248 Cr sits inside the business at any moment.

FY26: debtors at 11 days, inventory at 231 days — roughly 7.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 216 days, tighter than FY22's 312.

The full loop: cash goes out to suppliers and production on day 0; stock waits 231 days to sell; customers pay about 11 days after that; and suppliers themselves are paid at 26 days — netting out to the 216-day cycle.

In money terms: at FY26 sales of ₹2,109 Cr, each day of the cycle holds about ₹5.8 Cr — so the 216-day loop keeps roughly ₹1,248 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹349 Cr over the last 3 fiscal years against ₹162 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 5% and the ROIC − WACC spread is −9.3 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Dhampur Bio Organics Ltd earns a ROCE of 5% in FY26. That is up from a trough of 4% in FY25. Return on invested capital clears the cost of that capital by −9.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.2% net margin on 0.91× asset turns.

FY26 ROCE is 5%, recovered from a FY25 trough of 4% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 1.2% net margin × 0.91× asset turns × 2.26× balance-sheet leverage ≈ 2.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 2.7% − 12.0% = a −9.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 1.03.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Dhampur Bio Organics Ltd carries total debt of ₹1,060 Cr against shareholder equity of ₹1,027 Cr as of Jun 26, a debt-to-equity of 1.03. On the annual view that ratio went from 0.95 in FY22 to 1.03 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of ₹1,060 Cr against shareholder equity of ₹1,027 Cr — a debt-to-equity of 1.03. On the annual view, debt-to-equity went from 0.95 (FY22) to 1.03 (FY26). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: Foreign institutions cut 1.0 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions cut 1.0 points of Dhampur Bio Organics Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 0.3% of the company. Domestic institutions moved +0.4 points over the same window, to 0.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: −1.0 points over 8 quarters to 0.3%; Domestic institutions: +0.4 points over 8 quarters to 0.8%; Promoters: +0.0 points over 8 quarters to 50.8%.

🚨 Why the register moved: foreign institutions drove it (−1.0 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Dhampur Bio Organics Ltd: the Z-score reads 1.51. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

🚨 Why it matters: a Z-score of 1.51 is inside the distress zone — the balance sheet is a real risk, not a detail.

The safety line in one sentence: the Z-score reads 1.51.

Frequently asked questions